Astrana Health director receives 4,525-share stock grant

Mazdyasni Matthew reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Mazdyasni Matthew reported acquisition or exercise transactions in this Form 4 filing.

Astrana Health director Matthew Mazdyasni received an equity grant. The Form 4 reports an award of 4,525 shares of Astrana Health common stock at no purchase price, granted under the company’s 2024 Equity Incentive Plan.

These restricted shares will vest on the earlier of June 10, 2027 or the date of Astrana Health’s 2027 annual meeting of stockholders. After this grant, Mazdyasni directly owns 39,288 shares of Astrana Health common stock, including the 4,525 unvested restricted shares.

Insider Trade Summary

Grant/Award: 4,525 shares

Grant/Award 1 txn

Insider Mazdyasni Matthew

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,525	$0.00	$0.00

Holdings After Transaction: Common Stock — 39,288 shares (Direct)

Footnotes (2)

1. F1. Restricted shares of the Issuer's common stock granted pursuant to the Issuer's 2024 Equity Incentive Plan, which will vest on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.
2. F2. Includes 4,525 shares of restricted stock, which will vest on the earlier of June 10, 2027 or the date of the Issuer's 2027 annual meeting of stockholders.

Key Figures

Restricted stock grant: 4,525 shares Award price per share: $0.00 per share Total shares after grant: 39,288 shares +1 more

4 metrics

Restricted stock grant 4,525 shares Common stock award reported on Form 4

Award price per share $0.00 per share Grant/award acquisition (code A)

Total shares after grant 39,288 shares Directly owned following the transaction

Vesting date trigger June 10, 2027 Vests on this date or 2027 annual meeting, whichever is earlier

Key Terms

Restricted shares, 2024 Equity Incentive Plan, restricted stock, annual meeting of stockholders

4 terms

Restricted shares financial

"Restricted shares of the Issuer's common stock granted pursuant to the Issuer's 2024 Equity Incentive Plan"

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

2024 Equity Incentive Plan financial

"granted pursuant to the Issuer's 2024 Equity Incentive Plan, which will vest on the earlier of"

restricted stock financial

"Includes 4,525 shares of restricted stock, which will vest on the earlier of June 10, 2027"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

annual meeting of stockholders financial

"the date of the Issuer's 2027 annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Astrana Health (ASTH) report for Matthew Mazdyasni?

Astrana Health reported that director Matthew Mazdyasni received a grant of 4,525 shares of restricted common stock at no purchase price under the 2024 Equity Incentive Plan, increasing his direct holdings to 39,288 shares.

When do Matthew Mazdyasni’s new restricted shares in Astrana Health (ASTH) vest?

The 4,525 restricted shares granted to Matthew Mazdyasni will vest on the earlier of June 10, 2027 or the date of Astrana Health’s 2027 annual meeting of stockholders, according to the Form 4 footnotes.

How many Astrana Health (ASTH) shares does Matthew Mazdyasni own after this Form 4 grant?

Following the reported grant, Matthew Mazdyasni directly owns 39,288 shares of Astrana Health common stock. This total includes the 4,525 shares of restricted stock that will vest by the earlier of June 10, 2027 or the 2027 annual meeting.

Was Matthew Mazdyasni’s Astrana Health (ASTH) stock grant an open-market purchase?

No. The Form 4 shows an “A” code transaction, described as a grant or award, with a price per share of $0.00. This indicates a compensation-related equity award, not an open-market stock purchase.

Under which plan were Matthew Mazdyasni’s Astrana Health (ASTH) restricted shares granted?

The 4,525 restricted shares were granted under Astrana Health’s 2024 Equity Incentive Plan. The award consists of restricted common stock that vests on the earlier of June 10, 2027 or the company’s 2027 annual stockholder meeting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 04:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mazdyasni Matthew

(Last) (First) (Middle)

C/O ASTRANA HEALTH, INC.

1668 S. GARFIELD AVE, 2ND FLOOR

(Street)

ALHAMBRA CALIFORNIA 91801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Astrana Health, Inc. [ ASTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/10/2026		A		4,525(1)	A	$0	39,288(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted shares of the Issuer's common stock granted pursuant to the Issuer's 2024 Equity Incentive Plan, which will vest on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.

2. Includes 4,525 shares of restricted stock, which will vest on the earlier of June 10, 2027 or the date of the Issuer's 2027 annual meeting of stockholders.

	/s/ Kathy Diep, as Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)